Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Altimmune (ALT) over the last 7 years, with Q3 2018 value amounting to $173952.0.

  • Altimmune's Current Deferred Revenue rose 78063.59% to $173952.0 in Q3 2018 from the same period last year, while for Sep 2018 it was $173952.0, marking a year-over-year increase of 78063.59%. This contributed to the annual value of $19753.0 for FY2017, which is 0.0% changed from last year.
  • As of Q3 2018, Altimmune's Current Deferred Revenue stood at $173952.0, which was up 78063.59% from $172414.0 recorded in Q2 2018.
  • In the past 5 years, Altimmune's Current Deferred Revenue ranged from a high of $173952.0 in Q3 2018 and a low of $19753.0 during Q4 2016
  • Moreover, its 4-year median value for Current Deferred Revenue was $38503.0 (2017), whereas its average is $68111.5.
  • Per our database at Business Quant, Altimmune's Current Deferred Revenue crashed by 9287.96% in 2014 and then surged by 78063.59% in 2018.
  • Quarter analysis of 4 years shows Altimmune's Current Deferred Revenue stood at $62261.0 in 2014, then plummeted by 68.27% to $19753.0 in 2016, then changed by 0.0% to $19753.0 in 2017, then surged by 780.64% to $173952.0 in 2018.
  • Its Current Deferred Revenue was $173952.0 in Q3 2018, compared to $172414.0 in Q2 2018 and $44753.0 in Q1 2018.